PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/70 — A1

(11) International Publication Number: WO 96/27380

(43) International Publication Date: 12 September 1996 (12.09.96)

(21) International Application Number: PCT/US96/03159

(22) International Filing Date: 6 March 1996 (06.03.96)

(30) Priority Data:
08/399,262 — 6 March 1995 (06.03.95) — US
08/603,102 — 20 February 1996 (20.02.96) — US
08/609,448 — 1 March 1996 (01.03.96) — US

(71) Applicant: INTERNEURON PHARMACEUTICALS, INC. [US/US]; One Ledgemont Center, Suite 340, 99 Hayden Avenue, Lexington, MA 02173 (US).

(72) Inventors: SANDAGE, Bobby, Winston; 3 Stoneymeade Way, Acton, MA 01720 (US). FISHER, Marc; 29 High Street, Shrewsbury, MA 01455 (US). LOCKE, Kenneth, W.; 30 Ernies Drive, Littleton, MA 01460 (US).

(74) Agents: VILLACORTA, Gilberto, M. et al.; Lowe, Price, Leblanc & Becker, Suite 300, 99 Canal Center Plaza, Alexandria, VA 22314 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

9704272-5
IPOS's
copy

(54) Title: REDUCTION OF INFARCT VOLUME USING CITICOLINE

(57) Abstract

The invention is directed to a method of reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia, by the administration of citicoline shortly after an ischemic episode and continuing daily treatment for up to about 30 days, preferably for at least about 6 weeks. The method is useful in the treatment of stroke and severe head trauma patients and maximizes the chances for a full or substantially full recovery of the patient. Combination treatment regimens are also disclosed along with compositions for use therewith.